Cytomed Therapeutics, Through Its Wholly Owned Subsidiary, IPSC Depository Acquired The Licence And Certain Assets Of Cellsafe International For A Cash Consideration Of About RM 2.3M Or $490,000 To Be Funded From Internal Cash Resources
Portfolio Pulse from Benzinga Newsdesk
Cytomed Therapeutics, through its subsidiary IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000, funded from internal cash resources.
July 17, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytomed Therapeutics, through its subsidiary IPSC Depository, has acquired the license and certain assets of Cellsafe International for $490,000, funded from internal cash resources.
The acquisition of Cellsafe International's license and assets by Cytomed Therapeutics is likely to enhance its capabilities and portfolio, potentially leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100